D
Dorothy R. Barnard
Researcher at Halifax
Publications - 41
Citations - 3534
Dorothy R. Barnard is an academic researcher from Halifax. The author has contributed to research in topics: Leukemia & Thrombocytopenic purpura. The author has an hindex of 26, co-authored 41 publications receiving 3391 citations. Previous affiliations of Dorothy R. Barnard include Izaak Walton Killam Health Centre & Dalhousie University.
Papers
More filters
Journal ArticleDOI
Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry.
Paul Monagle,Margaret Adams,M Mahoney,K Ali,Dorothy R. Barnard,M Bernstein,L Brisson,M. David,Shalini Desai,M F Scully,Jacqueline Halton,Sara J. Israels,Lawrence Jardine,Michael Leaker,Patricia McCusker,M. Silva,Jianhong Wu,Ross Anderson,Maureen Andrew,M.P. Massicotte +19 more
TL;DR: The significant mortality and morbidity found in this study supports the need for international multicenter randomized clinical trials to determine optimal prophylactic and therapeutic treatment for children with DVT/PE.
Journal ArticleDOI
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group
William G. Woods,Steven Neudorf,Stuart H. Gold,Jean E. Sanders,Jonathan D. Buckley,Dorothy R. Barnard,Kathryn E. Dusenbery,J. Deswarte,Diane C. Arthur,Beverly J. Lange,Nathan L. Kobrinsky +10 more
TL;DR: Patients receiving intensive-timing induction therapy had superior long-term survival irrespective of postremission regimen received, and allogeneic BMT remains the treatment of choice for children and adolescents with AML in remission, when a matched related donor is available.
Journal ArticleDOI
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group
William G. Woods,Nathan L. Kobrinsky,Jonathan D. Buckley,Jae Won Lee,Jean E. Sanders,Steven Neudorf,Stuart H. Gold,Dorothy R. Barnard,J. Deswarte,Kathryn E. Dusenbery,Dagmar K. Kalousek,Diane C. Arthur,Beverly J. Lange +12 more
TL;DR: A prospective randomized trial in which 589 patients with AML were randomized at diagnosis to one of two induction approaches involving a 4-day cycle of five active chemotherapeutic agents, demonstrating a marked improvement in outcome.
Journal ArticleDOI
Distinctive Demography, Biology, and Outcome of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Children With Down Syndrome: Children's Cancer Group Studies 2861 and 2891
Beverly J. Lange,Nathan L. Kobrinsky,Dorothy R. Barnard,Diane C. Arthur,Jonathan D. Buckley,William B. Howells,Stuart H. Gold,Jean E. Sanders,Steven Neudorf,Franklin O. Smith,William G. Woods +10 more
TL;DR: AML in DS is demographically and biologically distinct from AML in other children, singularly responsive to conventional chemotherapy and may warrant even less therapy.
Journal ArticleDOI
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Beverly J. Lange,Franklin O. Smith,James H. Feusner,Dorothy R. Barnard,Patricia Dinndorf,Stephen A. Feig,Nyla A. Heerema,Carola A.S. Arndt,Robert J. Arceci,Nita Seibel,Margie Weiman,Kathryn E. Dusenbery,Kevin Shannon,Sandra Luna-Fineman,Robert B. Gerbing,Todd A. Alonzo,Todd A. Alonzo +16 more
TL;DR: CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensification, with mixed outcomes.